- Home
- PRPO vs YHC Comparison
PRPO vs YHC Comparison
Compare PRPO & YHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRPO
- YHC
- Stock Information
- Founded
- PRPO N/A
- YHC 2021
- Country
- PRPO United States
- YHC United States
- Employees
- PRPO N/A
- YHC N/A
- Industry
- PRPO Biotechnology: Laboratory Analytical Instruments
- YHC Beverages (Production/Distribution)
- Sector
- PRPO Industrials
- YHC Consumer Staples
- Exchange
- PRPO Nasdaq
- YHC Nasdaq
- Market Cap
- PRPO 12.3M
- YHC 12.3M
- IPO Year
- PRPO N/A
- YHC N/A
- Fundamental
- Price
- PRPO $10.14
- YHC $1.15
- Analyst Decision
- PRPO
- YHC Strong Buy
- Analyst Count
- PRPO 0
- YHC 2
- Target Price
- PRPO N/A
- YHC $5.00
- AVG Volume (30 Days)
- PRPO 13.1K
- YHC 113.4K
- Earning Date
- PRPO 03-28-2025
- YHC 03-31-2025
- Dividend Yield
- PRPO N/A
- YHC N/A
- EPS Growth
- PRPO N/A
- YHC N/A
- EPS
- PRPO N/A
- YHC N/A
- Revenue
- PRPO $17,411,000.00
- YHC $2,272,001.00
- Revenue This Year
- PRPO $75.18
- YHC $120.06
- Revenue Next Year
- PRPO N/A
- YHC $72.42
- P/E Ratio
- PRPO N/A
- YHC N/A
- Revenue Growth
- PRPO 31.31
- YHC 158.05
- 52 Week Low
- PRPO $4.31
- YHC $0.40
- 52 Week High
- PRPO $10.74
- YHC $2.45
- Technical
- Relative Strength Index (RSI)
- PRPO 85.00
- YHC N/A
- Support Level
- PRPO $7.02
- YHC N/A
- Resistance Level
- PRPO $7.54
- YHC N/A
- Average True Range (ATR)
- PRPO 0.50
- YHC 0.00
- MACD
- PRPO 0.29
- YHC 0.00
- Stochastic Oscillator
- PRPO 85.72
- YHC 0.00
About PRPO Precipio Inc.
Precipio Inc is a healthcare solutions company focused on cancer diagnostics. It focuses on addressing the problem of cancer misdiagnoses by developing solutions to mitigate the root causes of this problem in the form of diagnostic products, reagents and services. The company operates Clinical Laboratory Improvement Amendments laboratories in both the New Haven, Connecticut and Omaha, Nebraska locations providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. It provides new technologies to the oncology diagnostic laboratory market in the form of HemeScreen and IV-Cell product offerings. The company generates the majority of its revenue from third-party payers.